On the one hand, the company is struggling to stay competitive with its chief rival Eli Lilly, and on the other, compounders ...

The drugmaker released its second-quarter earnings report early Wednesday as it vowed to cut costs amid intensifying ...

Maziar Mike Doustdar, who was named as Novo Nordisk’s new CEO last week, spoke on a second quarter earnings call of ...

The maker of Ozempic and Wegovy has declared war on “fake” copycat weight-loss jabs as it battles a sales slowdown.

H1 sales growth for Novo Nordisk’s segment that includes Ozempic and Wegovy was down from the same period in 2024.

Sales of Novo Nordisk’s diabetes drugs including Ozempic slowed to grow at 8 per cent year on year in the first half, down sharply from its rate last year, as the company loses market share to rival ...

Stephen Millard, a senior economist at NIESR, said: “We think the current budget deficit will be around £40bn, or £41.2bn to ...

Novo Nordisk's already depressed share price has fallen again this morning, despite reporting an 18% increase in sales in the ...

Danish drugs giant Novo Nordisk posted a jump in second-quarter profit on Wednesday, against a backdrop of reduced sales forecasts, potential US tariffs and competitors threatening its blockbuster ...

STORY: Novo Nordisk said Wednesday it would cut costs as it takes on growing competition.The Danish firm faces a growing ...

Danish pharmaceutical giant Novo Nordisk posted a sharp rise in second-quarter net profit Wednesday, but rising competition ...